Why the study?
Cardiotoxic childhood cancer treatments place survivors at lifelong cardiovascular risk, and whether an existing ECG-AI model could detect elevated NT-proBNP using a single-lead Apple Watch ECG remained untested.
Does an ECG-AI model applied to a single-lead Apple Watch ECG accurately detect elevated NT-proBNP in adult survivors of childhood cancer?
Population
580 adult survivors of childhood cancer in the SJLIFE cohort
Comparison
ECG-AI model applied to Apple Watch ECG vs laboratory NT-proBNP
Design
Cohort diagnostic validation study
Key result
The ECG-AI model achieved an AUC of 0.84 for identifying elevated NT-proBNP levels (>300 pg/mL) in childhood cancer survivors using Apple Watch ECG.
Authors
Loading...
May support wearable ECG-AI screening for elevated NT-proBNP in survivors; leaves open prospective validation before clinical use.
Does an ECG-AI model applied to a single-lead Apple Watch ECG accurately detect elevated NT-proBNP in adult survivors of childhood cancer?
An existing ECG-AI model applied to single-lead Apple Watch ECGs can accurately detect elevated NT-proBNP in adult survivors of childhood cancer, offering a potential non-invasive screening tool.
Barr et al. (2026) studied this question. The ECG-AI model achieved an AUC of 0.84 for identifying elevated NT-proBNP levels (>300 pg/mL) in childhood cancer survivors using Apple Watch ECG.